SUPPLEMENTARY MATERIAL




Fig. S1 Patient disposition during the lead-in periods.

(A) Study 1; dapagliflozin add-on to metformin lead-in [8]. (B) Study 2; saxagliptin add-on to metformin lead-in [9].

AE, adverse event; DPP-4, dipeptidyl peptidase-4.

^aStratum B of study 2 is not included in the analyses of the lead-in period because these patients had previously been receiving DPP-4 inhibitor therapy.